Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After drug eluting stent Implantation Receiving Clopidogrel.

Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After drug eluting stent Implantation Receiving Clopidogrel. - Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After drug eluting stent Implantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008058

Enrollment

100

Registered

2012-05-30

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)coronary artery disease who received clopidogrel 75mg per day and aspirin 100mg pre day. 2)The patient who is going to undergo percutaneous coronary intervention with DES. 3)The patient who is eligible to VerifyNow measurement. 4)The patient who agree with a Document consent after informed consent.

Exclusion criteria

Exclusion criteria: 1)The patient who has a plan to receive surgical procedure. 2)The patient who received anticoagulant agent, thrombolytic drug, antiplatelet drug other than aspirin or clopidogrel. 3)There is contraindication of aspirin or clopidogrel. 4)The patient who do not agree with this trial. 5)inappropriate patient.

Design outcomes

Primary

Measure	Time frame
frequency of intra stent thrombus in CYP2C19 carriers.	—

Countries

Japan

Contacts

Public ContactNatsuko Tahara

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

macadamia_chocolate@icloud.com81-78-382-5846

Outcome results